Alivus Life Sciences has acquired IQGEN-X Pharma Pvt Ltd for an undisclosed amount. This corporate acquisition brings IQGEN-X’s specialized expertise in developing and commercializing complex generics for regulated export markets under the Alivus umbrella. IQGEN-X Pharma Pvt Ltd has built its foundation on creating innovation and quality-based pharmaceutical products, focusing on establishing intellectual property assets through its capability to identify, develop, regulate, and commercialize specialized generic medicines for global distribution.
The core philosophy of IQGEN-X centers on "Build Quality into the Product through Innovative Research to affordably produce Safe & Effective Medicines." This comprehensive approach involves meticulous complex product selection, an IT-based execution strategy designed for full-proof delivery of its business plan, and the strategic in-house development of business-critical Active Pharmaceutical Ingredients (API). These robust capabilities are expected to significantly enhance Alivus Life Sciences' existing product development pipeline, operational efficiencies, and market responsiveness.
IQGEN-X’s key differentiators, including its highly experienced team with demonstrable skills, a differentiated business strategy, a complete understanding of current and future regulatory and quality mindsets, and proven execution excellence, are now integrated into Alivus Life Sciences. This integration is anticipated to strengthen Alivus’s overall ability to navigate complex pharmaceutical development and stringent regulatory landscapes, while expanding its footprint and competitive offerings in key international export markets.
The combined entity is well-positioned to leverage IQGEN-X’s specialized knowledge, intellectual property assets, and operational strengths to accelerate the development and market entry of high-quality, affordable medicines. This strategic move aims to bolster Alivus Life Sciences’ position as a comprehensive pharmaceutical player, enhancing its capacity for innovation and significantly expanding its reach and influence within the global generics market.